UNSPSC 51363100: Hypnotics, synthesized

This classification denotes Hypnotics composed of multiple constituents, with no dominant constituent.

UNSPSC 51363100 Hypnotics, synthesized is a Class code that in practice encompasses a broader range of pharmaceutical products and drug-related services than the code name alone suggests. Recent state and local solicitations under this code show purchasing activity for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesaler networks, and exploratory procurement for direct-to-manufacturer prescription fulfillment programs. The issuing bodies are county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Vendors pursuing this code should expect to meet rigorous compliance requirements, including FDA Good Manufacturing Practice certification, Drug Supply Chain Security Act adherence, E-Verify employment verification, comprehensive liability and workers' compensation insurance, and often the ability to distribute through established wholesaler networks and contracted partners rather than direct to end-user agencies.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multi-state scope extending to Oregon and other cooperative purchasing members. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, awarded on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas HHS Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and wholesaler arrangements. MMCAP released RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026 and mandatory distribution through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC; evaluation weighted 75 percent on price competitiveness, with vendors paying a 3 percent administrative fee and facing performance penalties of $200 to $1,500 per violation.